Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Abbott Laboratories

Related ABT
Benzinga's Top Upgrades
Barclays Upgrades Abbott, Sees 'Selling Overdone'
Boston Arrives Late To The Mitral Valve Party (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Abbott Laboratories (NYSE: ABT), but lowered its price target from $87.00 to $39.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Abbott Laboratories closed on Tuesday at $33.36.

Latest Ratings for ABT

Oct 2015BarclaysUpgradesEqual-weightOverweight
Aug 2015Credit SuisseAssumesOutperform
Aug 2015JefferiesMaintainsHold

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (ABT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters